Telcagepant is an investigational drug for migraine. It is an antagonist of CGRP receptors that is administered orally, researched and developed by Merck & Co. Merck & Co., Inc. (MSD in Spain) has announced that a Phase III clinical trial, the telcagepant has significantly improved moderate to severe migraine attacks, including migraine pain and symptoms associated therewith, compared to placebo.
This drug, formerly known as MK-0974, is a receptor antagonist gene-related peptide of calcitonin (CGRP), which is administered orally and is under investigation. According to the results of the study, overall rates of adverse events were similar to placebo. The new data was presented in London at the European Congress of Headache and the International Congress of the Migraine Foundation.
“This data adds to the clinical program of telcagepant as a possible treatment for acute migraine,” said Tony W. Ho, senior clinical research at Merck Research Laboratories.
The results reported are from an international clinical trial, multicenter, randomized, placebo-controlled trial in adult patients with acute migraine.
In total, 1,703 randomized patients participated in the study, of whom 1,294 received the drug. The 1,294 crisis patients experienced moderate to severe migraine, as defined by the International Classification of Headache II of the International Headache Society, who were treated with telcagepant in doses of 300mg, 150mg and 50mg (n = 177) or placebo (n = 365).
The overall effect of treatment was evaluated by analyzing five primary endpoints two hours after receiving the dose: disappearance of pain (reduction to no pain), pain relief (reduction to mild or no pain), absence photophobia (sensitivity to light), absence of phonophobia (sensitivity to sound) and absence of nausea were all found. With telcagepant (300mg) all five primary endpoints of the study were completed